XML 64 R54.htm IDEA: XBRL DOCUMENT
v3.21.2

Regeneron License and Collaboration Arrangement - Additional Information (Details) - USD ($) $ in Millions |  |  | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | ---
Sep. 30, 2020 | Jul. 29, 2016 | Sep. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2020 | Sep. 30, 2019 | Jun. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2018 | Dec. 31, 2017
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Contract Assets |  |  |  |  |  |  |  |  | $ 0.0 |  |
Licence agreement cumulative revenue recognised |  |  |  |  |  |  |  | $ 35.3 |  |  |
Regeneron Pharmaceuticals, Inc. |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Contract Assets |  |  |  |  |  |  | $ 10.0 |  |  |  |
Non refundable upfront payment received |  |  |  |  |  |  |  | 25.0 |  |  |
Additional payment for research funding received |  |  |  |  |  |  |  | $ 20.0 |  | $ 5.0 | $ 5.0
License agreement termination description |  |  |  |  |  |  |  | twelve years |  |  |
Contract research term period |  | 5 years |  |  |  |  |  |  |  |  |
Upfront payment | $ 25.0 | $ 25.0 |  |  |  |  |  | $ 25.0 |  |  |
Licence agreement cumulative revenue recognised |  |  | $ 3.4 |  | $ 5.0 |  | $ 10.0 | 4.3 |  |  |
License agreement cumulative revenue reduction recognised |  |  |  |  |  | $ 6.6 |  |  |  |  |
Increase in estimated transaction price |  |  |  |  | $ 10.0 |  |  |  |  |  |
Contract liability |  |  |  |  |  |  |  | 10.1 | 19.4 |  |
Regeneron Pharmaceuticals, Inc. | Change in Accounting Estimate |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
License agreement cumulative revenue reduction recognised |  |  |  | $ 4.0 |  |  |  |  |  |  |
Regeneron Pharmaceuticals, Inc. | Maximum |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Licence agreement additional amount payable of option exercise fees |  |  |  |  |  |  |  | $ 100.0 |  |  |
Regeneron Pharmaceuticals, Inc. | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Licence agreement cumulative revenue recognised |  |  |  |  |  |  |  |  | $ 25.6 |  |

X
- Definition Contract Assets + References No definition available. + Details
Name: | acet_ContractAssets
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contract liability. + References No definition available. + Details
Name: | acet_ContractLiability
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contract research term period. + References No definition available. + Details
Name: | acet_ContractResearchTermPeriod
Namespace Prefix: | acet_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Additional amount payable of option exercise fees. + References No definition available. + Details
Name: | acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cumulative revenue recognised. + References No definition available. + Details
Name: | acet_LicenceAgreementCumulativeRevenueRecognised
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront payment. + References No definition available. + Details
Name: | acet_LicenceAgreementUpfrontPayment
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Additional payment for research funding received. + References No definition available. + Details
Name: | acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License agreement cumulative revenue reduction recognised. + References No definition available. + Details
Name: | acet_LicenseAgreementCumulativeRevenueReductionRecognised
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License agreement termination description. + References No definition available. + Details
Name: | acet_LicenseAgreementTerminationDescription
Namespace Prefix: | acet_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Non refundable upfront payment received. + References No definition available. + Details
Name: | acet_NonRefundableUpfrontPaymentReceived
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_RegeneronPharmaceuticalsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |